PLAYBOOK · NUTRA · US
Card Acquiring for US-Based Nutraceutical Brands
FDA DSHEA supplement programmes
US nutraceutical brands operate under the Dietary Supplement Health and Education Act (DSHEA) 1994, which treats supplements as food rather than drugs and shifts post-market enforcement onto the FDA and FTC. That regulatory shape — plus card scheme treatment of nutra as inherently high-chargeback — is what makes domestic acquiring so much harder than the products themselves suggest.
WHY THIS COMBINATION IS HARD
What goes wrong when generalist acquirers see this profile.
DSHEA does not pre-approve your product or your claims
Under DSHEA, neither the FDA nor any other regulator vets your supplement before sale. Acquirers know this, so underwriting compensates by scrutinising your label, your structure-function claims, your FDA disclaimer and your evidence file in ways that generalist underwriters simply do not understand.
FTC substantiation risk sits on the acquirer's chargeback ledger
The FTC requires competent and reliable scientific evidence for every advertising claim. When claims drift — particularly on weight loss, sexual performance, cognitive or immune products — chargebacks, INR disputes and FTC actions follow, and the acquirer wears the loss. Underwriters price that risk into reserves.
Visa VAMP and Mastercard MATCH exposure is structural, not occasional
Nutra under MCC 5122 or 5499 is treated as elevated-risk by both schemes. A brand that crosses Visa VAMP chargeback ratio thresholds, or lands on MATCH for excessive chargebacks, can lose acquiring across the entire US market for years — generalist acquirers offboard at the first sign of trouble.
Subscription and free-trial models trigger negative-option rules
FTC's Negative Option Rule and the Restore Online Shoppers' Confidence Act (ROSCA) govern continuity billing. Acquirers underwriting trial-to-subscription nutra need documented cancellation flows, clear disclosure screens and refund policies — most generalist PSPs will not even take the call.
Ingredient risk is binary for underwriting
DSHEA permits a wide ingredient set, but acquirers maintain internal prohibited lists covering SARMs, kratom, CBD, nootropic stacks, hormone precursors and anything resembling a New Dietary Ingredient without an NDI notification. One flagged SKU can sink the whole MID application.
cGMP (21 CFR Part 111) becomes an underwriting document
Specialist acquirers will ask for your contract manufacturer's cGMP certification, COAs and recall procedures. Generalist PSPs do not know to ask, then offboard six months in when a quality complaint surfaces.
WHAT TO EXPECT
Realistic terms for this combination.
ROLLING RESERVE
10-15% rolling reserve over 180 days for straight-sale nutra; 15-20% over 180-270 days for subscription/free-trial models
SETTLEMENT
T+2 to T+7 domestically; subscription nutra often pushed to T+7 or longer until chargeback profile is established
MCC CODES
5122 (Drugs, Drug Proprietors, Druggist Sundries), 5499 (Misc Food Stores - Convenience Stores and Specialty Markets), occasionally 5912 for online vitamin retail
Scheme reporting: Visa Acquirer Monitoring Programme (VAMP) and the legacy chargeback thresholds (0.9% standard, 1.8% excessive) are the primary scheme exposure. Mastercard's Excessive Chargeback Programme (ECP) and Excessive Fraud Merchant (EFM) tiers add a second monitoring layer, and free-trial nutra is specifically called out in scheme guidance on deceptive marketing.
ACQUIRER LANDSCAPE
Who actually underwrites this combination.
The active US nutra acquiring pool is dominated by domestic processors with dedicated high-risk verticals, sponsor-bank programmes underwriting through ISO channels, and a smaller layer of offshore acquirers willing to take subscription/continuity models. Generalist acquirers — the names a merchant gets from a typical aggregator signup — either decline outright or board the merchant and then offboard the moment chargebacks normalise above 0.7%. Specialist acquirers price for the risk from day one and stay through volatility.
HOW ICETREE APPROACHES IT
Our approach for merchants in this combination.
- We pre-screen your label, claims and ingredient list against acquirer prohibited lists before any application goes out, so you don't burn underwriting attempts on a deal that was never going to clear.
- We match free-trial and subscription nutra to acquirers with documented ROSCA-compliant programmes — not generalists who will offboard at the first chargeback spike.
- We negotiate reserves against your actual chargeback ratio and refund policy, not the worst-case nutra template the acquirer's risk team starts from.
- We structure multi-MID redundancy across domestic and offshore acquirers so a single VAMP event doesn't take the business offline.
- We're paid by the PSP on placement, never by you — our incentive is getting a programme that survives month 12, not just closing the application.
FAQ
Common questions answered.
Want IceTree on your side?
Run the Approval Predictor for a 2-minute estimate of your acquirer fit, expected reserve range, and what to prepare — specific to United States and FDA DSHEA.